Last reviewed · How we verify

Antiplatelet therapy

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

Antiplatelet therapy is a Antiplatelet agent Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Acute coronary syndrome, Secondary prevention of myocardial infarction, Stroke prevention. Also known as: ticagrelor, aspirin, The brand name of clopidogrel is Plavix., The brand name of cilostazol is Pletaal..

Antiplatelet therapy inhibits platelet aggregation to prevent blood clot formation and reduce thrombotic events.

Antiplatelet therapy inhibits platelet aggregation to prevent blood clot formation and reduce thrombotic events. Used for Acute coronary syndrome, Secondary prevention of myocardial infarction, Stroke prevention.

At a glance

Generic nameAntiplatelet therapy
Also known asticagrelor, aspirin, The brand name of clopidogrel is Plavix., The brand name of cilostazol is Pletaal.
SponsorAssistance Publique - Hôpitaux de Paris
Drug classAntiplatelet agent
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Antiplatelet agents work by interfering with platelet activation and adhesion through various mechanisms, such as inhibiting cyclooxygenase (aspirin), blocking ADP receptors (clopidogrel, ticagrelor), or inhibiting phosphodiesterase. This prevents platelets from clumping together and forming pathological thrombi that can occlude blood vessels and cause myocardial infarction or stroke.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Antiplatelet therapy

What is Antiplatelet therapy?

Antiplatelet therapy is a Antiplatelet agent drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Acute coronary syndrome, Secondary prevention of myocardial infarction, Stroke prevention.

How does Antiplatelet therapy work?

Antiplatelet therapy inhibits platelet aggregation to prevent blood clot formation and reduce thrombotic events.

What is Antiplatelet therapy used for?

Antiplatelet therapy is indicated for Acute coronary syndrome, Secondary prevention of myocardial infarction, Stroke prevention, Peripheral arterial disease.

Who makes Antiplatelet therapy?

Antiplatelet therapy is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Antiplatelet therapy also known as anything else?

Antiplatelet therapy is also known as ticagrelor, aspirin, The brand name of clopidogrel is Plavix., The brand name of cilostazol is Pletaal..

What drug class is Antiplatelet therapy in?

Antiplatelet therapy belongs to the Antiplatelet agent class. See all Antiplatelet agent drugs at /class/antiplatelet-agent.

What development phase is Antiplatelet therapy in?

Antiplatelet therapy is FDA-approved (marketed).

What are the side effects of Antiplatelet therapy?

Common side effects of Antiplatelet therapy include Bleeding, Gastrointestinal bleeding, Dyspepsia, Intracranial hemorrhage.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing